190 related articles for article (PubMed ID: 33310702)
1. Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells.
Patel KR; Rodriguez Benavente MC; Lorenz WW; Mace EM; Barb AW
J Biol Chem; 2021; 296():100183. PubMed ID: 33310702
[TBL] [Abstract][Full Text] [Related]
2. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
3. CD16a with oligomannose-type
Subedi GP; Barb AW
J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
[TBL] [Abstract][Full Text] [Related]
4. Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes.
Patel KR; Roberts JT; Barb AW
Glycobiology; 2020 Jul; 30(7):427-432. PubMed ID: 31967297
[TBL] [Abstract][Full Text] [Related]
5. Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.
Roberts JT; Patel KR; Barb AW
Mol Cell Proteomics; 2020 Feb; 19(2):362-374. PubMed ID: 31888963
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW
Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360
[TBL] [Abstract][Full Text] [Related]
7. Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability.
Patel KR; Nott JD; Barb AW
Mol Cell Proteomics; 2019 Nov; 18(11):2178-2190. PubMed ID: 31467031
[TBL] [Abstract][Full Text] [Related]
8. The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
Kremer PG; Barb AW
J Biol Chem; 2022 Sep; 298(9):102329. PubMed ID: 35921896
[TBL] [Abstract][Full Text] [Related]
9. Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC.
Benavente MCR; Hakeem ZA; Davis AR; Murray NB; Azadi P; Mace EM; Barb AW
Sci Rep; 2024 Apr; 14(1):7938. PubMed ID: 38575779
[TBL] [Abstract][Full Text] [Related]
10. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
Falconer DJ; Subedi GP; Marcella AM; Barb AW
ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
[TBL] [Abstract][Full Text] [Related]
11. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.
Roberts JT; Barb AW
J Biol Chem; 2018 Dec; 293(51):19899-19908. PubMed ID: 30361439
[TBL] [Abstract][Full Text] [Related]
12. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells.
Mishra HK; Pore N; Michelotti EF; Walcheck B
Cancer Immunol Immunother; 2018 Sep; 67(9):1407-1416. PubMed ID: 29978334
[TBL] [Abstract][Full Text] [Related]
13. ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation.
Lajoie L; Congy-Jolivet N; Bolzec A; Gouilleux-Gruart V; Sicard E; Sung HC; Peiretti F; Moreau T; Vié H; Clémenceau B; Thibault G
J Immunol; 2014 Jan; 192(2):741-51. PubMed ID: 24337742
[TBL] [Abstract][Full Text] [Related]
14. The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites.
Lampros EA; Kremer PG; Aguilar Díaz de León JS; Roberts ET; Rodriguez Benavente MC; Amster IJ; Barb AW
Curr Res Immunol; 2022; 3():128-135. PubMed ID: 35712026
[TBL] [Abstract][Full Text] [Related]
15. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
16. Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.
Jing Y; Ni Z; Wu J; Higgins L; Markowski TW; Kaufman DS; Walcheck B
PLoS One; 2015; 10(3):e0121788. PubMed ID: 25816339
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development.
Victor AR; Weigel C; Scoville SD; Chan WK; Chatman K; Nemer MM; Mao C; Young KA; Zhang J; Yu J; Freud AG; Oakes CC; Caligiuri MA
J Immunol; 2018 Jan; 200(2):565-572. PubMed ID: 29229679
[TBL] [Abstract][Full Text] [Related]
18. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
Front Immunol; 2022; 13():841859. PubMed ID: 35281028
[TBL] [Abstract][Full Text] [Related]
19. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor.
Subedi GP; Barb AW
MAbs; 2016; 8(8):1512-1524. PubMed ID: 27492264
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-affinity anti-CD16A allotype-independent human antibody domains.
Li W; Yang H; Dimitrov DS
Exp Mol Pathol; 2016 Oct; 101(2):281-289. PubMed ID: 27712994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
